CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 34 enrolled
Drug / intervention
Depot medroxyprogesterone acetate (DMPA)drug
Likely dose
Depot medroxyprogesterone acetate (DMPA) 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01461824
NCT01461824Phase 3Completed
CompareCT.gov

Relationship Between Drug Exposure and DNA Markers With Depot Medroxyprogesterone Acetate-associated Side Effects in Adolescents

Nationwide Children's Hospital·interventional·Posted Oct 28, 2011·Updated Apr 23, 2018

In Brief

A Phase 3 clinical trial evaluating Depot medroxyprogesterone acetate (DMPA) for Weight Gain and 2 related conditions. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The investigators are doing this study to look at how different doses of the Depot medroxyprogesterone acetate (DMPA) shot effect weight gain and bone mineral density in teens. The investigators hope that what the investigators learn from this study will be used to develop ways to keep girls from gaining weight or losing bone density when receiving DMPA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWeight Gain, Disorder of Bone Density and Structure, Unspecified, Uterine Bleeding
CountriesUnited States
CollaboratorsSociety of Family Planning

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 28, 2011
Enrollment StartSep 1, 2011
Primary CompletionApr 1, 2015
Study CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 14.7 years ago

Interventions

Depot medroxyprogesterone acetate (DMPA)drug

75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months